Navigation Links
Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
Date:6/24/2008

Durezol is First Ophthalmic Steroid Indicated for Inflammation and Pain

TAMPA, Fla., June 24 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved its new drug application for Durezol(TM) (difluprednate ophthalmic emulsion) 0.05%, a topical steroid for the treatment of postoperative ocular inflammation and pain. The approval came after a six month priority review.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO )

"Durezol, our first product to be approved by the FDA, is a potent topical steroid that works rapidly and effectively to resolve postoperative inflammation and pain," said Barry Butler, President and CEO of Sirion Therapeutics, Inc. "We look forward to launching the first innovation in the strong steroid class in more than 35 years, and the first steroid to have an indication for the treatment of postoperative pain. We believe that having access to a steroid that treats both inflammation and pain gives physicians a more complete treatment approach."

In two Phase 3 trials evaluating Durezol in patients diagnosed with significant postoperative inflammation (more than 10 anterior chamber cells), Durezol rapidly reduced inflammation and pain. Mean intraocular pressure (IOP) for all study groups remained within the normal range throughout the study.

"Rapid resolution of inflammation and pain is very important following ocular surgery," said Dr. Michael Korenfeld, M.D., Assistant Clinical Professor of Ophthalmology and Visual Sciences, Washington University, St. Louis, MO, and principal investigator for the Phase 3 trials. "It is important to point out that in these Phase 3 studies, patients were dosed for the first time after the ocular trauma from surgery had occurred. The results from these studi
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sirion Therapeutics Supports Ophthalmic Education
2. Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
3. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
4. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Calif. (PRWEB) June 02, 2015 ... build-to-order, independent blade-based and rackmount computing and storage ... announced the launch of its high density scale-out, ... Cirrascale Slipstream™ RM1622D . The high density, ... E3-1200 v4 product family with Intel® Iris™ Pro ...
(Date:6/2/2015)... Pa. , June 2, 2015   ... be attending the BIO Exhibition 2015 in ... Exhibition, the world,s largest biotechnology gathering, allows influential ... high-level executives, where they can evaluate emerging technologies ... significant eClinical expertise in the design, implementation and ...
(Date:6/2/2015)... Pa. , June 2, 2015   BioClinica ... and technology provider, today announced that David Peters ... been named Executive Vice President and Chief Financial Officer ... 2015. Peters brings more than 25 years ... pharmaceutical services. "David has extensive and deep knowledge in ...
(Date:6/2/2015)... June 2, 2015   Sigma-Aldrich Corporation (NASDAQ: ... Technology company, announced today it has entered into ... launch genetically engineered human neural differentiated cells and ... of neurological diseases. These new products, in combination ... versatile tools for the study of central nervous ...
Breaking Biology Technology:Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 2Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 3YPrime at BIO Exhibition in Philadelphia and DIA in Washington DC during the month of June 2BioClinica Names David Peters New Chief Financial Officer 2Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 2Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 3
... (NASDAQ: ONTY ) today reported a net loss of ... for the quarter ended June 30, 2010 , compared with a net ... diluted share for the comparable period in 2009. Oncothyreon also reported a net ... diluted share for the six months ended June 30, 2010 , compared ...
... PRINCETON, N.J. , Aug. 5 Signum Biosciences, Inc. today ... Barrier Therapeutics, as Chief Executive Officer.  Dr. Shroot replaces Dr. Gregory ... a member of the board. , ... " Braham Shroot brings to Signum an outstanding ...
... Aug. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE ... in the Phase I portion of its Phase I/II ... with myelofibrosis. In total, 21 patients were treated in ... shown significant activity in reducing spleen size and controlling ...
Cached Biology Technology:Oncothyreon reports second quarter 2010 financial results 2Oncothyreon reports second quarter 2010 financial results 3Oncothyreon reports second quarter 2010 financial results 4Oncothyreon reports second quarter 2010 financial results 5Oncothyreon reports second quarter 2010 financial results 6Oncothyreon reports second quarter 2010 financial results 7Oncothyreon reports second quarter 2010 financial results 8Signum Biosciences Names Braham Shroot as Chief Executive Officer 2YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study 2YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study 3YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study 4YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study 5
(Date:5/22/2015)... May 22, 2015 According to ... Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), ... and Utilities, Consumer and Home) - Global Forecast to ... from $2.77 Billion in 2015 to $6.19 Billion by ... Browse 79 market data Tables and   43 Figures ...
(Date:5/19/2015)... Sweden , May 18, 2015 ... fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one ... from June until and including Q3 2015 and the sensors ... . Communicated order values for 2015 hereby amount to ... for Q1 2015 of 140 MSEK and a number of ...
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... OAK RIDGE, Tenn., June 2, 2010 -- Carbon ... States can now be tracked with unprecedented resolution ... National Laboratory. A team led by Tristram ... high-resolution national inventory datasets to pinpoint agricultural-based carbon ...
... desert could change the composition of microbial communities in ... this month in the journal FEMS Microbiology Letters ... dust particles consisting of soil particles are lifted high ... deposited on the ocean surface. "Desert dust particles ...
... an event that affects cell function by altering gene expression ... cell researchers at UCLA, a finding that could have implications ... cell lines. The team of scientists discovered a relationship ... and regulate access to DNA in the nucleus of a ...
Cached Biology News:ORNL sows seeds with new agricultural carbon accounting tool 2Bacterioplankton responses to desert dust in the (sub)tropical northeast Atlantic 2UCLA stem cell researchers uncover previously unknown patterns in DNA methylation 2
CircuLex Anti-Human S100P Polyclonal Antibody Research Focus: proliferation Storage: -20C Shipping Temperature: 4C...
HAMP Immunogen: HAMP (AAH20612, 25 a.a. ~ 85 a.a) full length recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
p38 MAP Kinase gamma Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Goat polyclonal to JIK ( Abpromise for all tested applications). Antigen: Synthetic peptide: HKKDHVFIRDEAGHGD, corresponding to amino acids 396-411 of Human JIK. Entrez Gene ID: 51347 Swi...
Biology Products: